Although CMS sent a memo to state Medicaid directors about this designation in 2016 (CMS, 2016e) and updated Chapter 16B of the Medicare Managed Care Manual (CMS, 2016b) to include more description of the category, few of the states or plans with which we spoke during our case studies or at our in-person meeting reported that they understood how these plans worked or why it might be beneficial for them to pursue this designation
These findings indicate that the most affected component of OXPHOS in ASD patients is complex I, but abnormalities in the activity of other complexes, such as complexes III, IV, and V, can also be found
Critical distinction for prescribers: Category 1 reclassification does not mean FDA approval
[DOI] [PubMed] [Google Scholar] 52
The Methionine Cycle Watch our accompanying video here The methionine cycle is the second key process that works alongside the folate cycle to produce SAMe (S-Adenosyl-Methionine), driving methylation